Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 3, 2015, Pages 235-244

  Shoji, Tetsuo ^a,b   Marubayashi, Seiji ^b   Shigematsu, Takashi ^b   Iseki, Kunitoshi ^b   Tsubakihara, Yoshiharu ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

Author keywords

Chronic kidney disease mineral bone disorder; Fatality; Hemodialysis; Incident cardiovascular disease; Mortality; Phosphate binders; Vitamin D

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ALUMINUM HYDROXIDE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CALCIUM BASED PHOSPHATE BINDER; CALCIUM CARBONATE; CARDIOVASCULAR AGENT; FALECALCITRIOL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SERUM ALBUMIN; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR ACTIVATOR; CALCITRIOL RECEPTOR; CHELATING AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BONE DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INFECTION; JAPAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PHOSPHATE BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SUDDEN DEATH; TREATMENT DURATION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; FOLLOW UP; HEMODIALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL MODEL;

AGED; CARDIOVASCULAR DISEASES; CHELATING AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHATES; RECEPTORS, CALCITRIOL; REGISTRIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84930274509     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12274     Document Type: Article

References (51)

1. Moe S, Drueke T, Cunningham J etal. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
3. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525-531.
4. Kalantar-Zadeh K, Kuwae N, Regidor DL etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
5. Nakai S, Akiba T, Kazama J etal. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;12:49-54.
6. Drechsler C, Pilz S, Obermayer-Pietsch B etal. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010;31:2253-2261.
7. Teng M, Wolf M, Ofsthun MN etal. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
8. Melamed ML, Eustace JA, Plantinga L etal. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70:351-357.
9. Wolf M, Shah A, Gutierrez O etal. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013.
10. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J etal. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-1078.
11. Tentori F, Albert JM, Young EW etal. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009;24:963-972.
12. Shoji T, Shinohara K, Kimoto E etal. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
13. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-238.
14. Xiang W, Kong J, Chen S etal. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125-132.
15. Suematsu Y, Nishizawa Y, Shioi A etal. Effect of 1, 25-dihydroxyvitamin D3 on induction of scavenger receptor and differentiation of 12-O-tetradecanoylphorbol-13-acetate-treated THP-1 human monocyte like cells. J Cell Physiol 1995;165:547-555.
16. Tabata T, Suzuki R, Kikunami K etal. The effect of 1 alpha-hydroxyvitamin D3 on cell-mediated immunity in hemodialyzed patients. J Clin Endocrinol Metab 1986;63:1218-1221.
17. Kautzky-Willer A, Pacini G, Barnas U etal. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995;47:200-206.
18. Manenti L, Vaglio A, Pasquali S. Increased fetuin-A levels following treatment with a vitamin D analog. Kidney Int 2010;78:1187-1189; author reply 1187-1189.
19. Lim K, Lu TS, Molostvov G etal. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012;125:2243-2255.
20. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000;36:820-825.
21. Iseki K, Fukiyama K, Okinawa_Dialysis_Study_Group. Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. The Okinawa Dialysis Study (OKIDS) Group. Nephrol Dial Transplant 2000;15:1808-1813.
22. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
23. Smith GL, Masoudi FA, Shlipak MG, Krumholz HM, Parikh CR. Renal impairment predicts long-term mortality risk after acute myocardial infarction. J Am Soc Nephrol 2008;19:141-150.
24. Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 2001;38:S4-7.
25. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition-need for strict control of risk factors. Intern Med 2005;44:179-187.
26. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:1112-1120.
27. Palmer SC, Hayen A, Macaskill P etal. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305:1119-1127.
28. Nakai S, Wada A, Kitaoka T etal. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006;10:476-497.
29. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525.
30. Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients-clinical implications and therapeutic guidelines. Ther Apher Dial 2006;10:305-315.
31. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
32. Degoulet P, Legrain M, Reach I etal. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982;31:103-110.
33. Klahr S, Slatopolsky E. Toxicity of parathyroid hormone in uremia. Annu Rev Med 1986;37:71-78.
34. Massry SG, Goldstein DA. The search for uremic toxin(s) "X" "X" = PTH. Clin Nephrol 1979;11:181-189.
35. Faul C, Amaral AP, Oskouei B etal. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
36. Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004;15:733-742.
37. Liu Y, Coresh J, Eustace JA etal. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459.
38. Fouque D, Kalantar-Zadeh K, Kopple J etal. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391-398.
39. Taniguchi M, Fukagawa M, Fujii N etal. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 2013;17:221-228.
40. Caliskan Y, Demirturk M, Ozkok A etal. Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrol Dial Transplant 2010;25:2685-2690.
41. Wang L, Jerosch-Herold M, Jacobs DR, Jr, Shahar E, Detrano R, Folsom AR. Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2006;48:1018-1026.
42. Fukuda D, Yoshiyama M, Shimada K etal. Relation between aortic stiffness and coronary flow reserve in patients with coronary artery disease. Heart 2006;92:759-762.
43. Son BK, Akishita M, Iijima K, Eto M, Ouchi Y. Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 2008;15:63-68.
44. Park JW, Yook JM, Ryu HM etal. Phosphate-induced apoptosis in human peritoneal mesothelial cells in vitro. Am J Nephrol 2011;34:77-86.
45. Jamal SA, Vandermeer B, Raggi P etal. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382:1268-1277.
46. Isakova T, Gutierrez OM, Chang Y etal. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-396.
47. Lopes AA, Tong L, Thumma J etal. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60:90-101.
48. Cannata-Andia JB, Fernandez-Martin JL, Locatelli F etal. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84:998-1008.
49. Braunlin W, Zhorov E, Guo A etal. Bile acid binding to sevelamer HCl. Kidney Int 2002;62:611-619.
50. Wanner C, Krane V, Marz W etal. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
51. Tentori F, Blayney MJ, Albert JM etal. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530.